Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the production of Tamsulosin Hydrochloride raw material by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice for the marketing application of Tamsulosin Hydrochloride [1] - Tamsulosin Hydrochloride is a third-generation highly selective long-acting α1 inhibitor, used for the treatment of benign prostatic hyperplasia [1] Group 2: Product Background - The drug was developed by Japan's Yamanouchi Pharmaceutical and was approved for marketing by the U.S. Food and Drug Administration in July 1992 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval was granted to Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd. [1] - The company has invested approximately RMB 1.5 million in research and development for Tamsulosin hydrochloride [1] - The drug is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] Group 2: Regulatory and Market Implications - The approval indicates that the raw material meets the regulatory requirements for domestic drug registration, allowing it to be sold in the domestic market [1] - This experience will be valuable for the company in future raw material drug applications [1] - The approval is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval for Tamsulosin hydrochloride indicates that the raw material meets domestic drug registration requirements and can be sold in the domestic market [1] - The company has invested approximately RMB 1.5 million in research and development for this drug [1] - The approval process has provided valuable experience for the company in future raw material drug applications [1] Group 2: Product Information - Tamsulosin hydrochloride is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in July 2024, which was accepted [1] Group 3: Financial Impact - The approval of Tamsulosin hydrochloride is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced the election of Mr. Zhao Yong as the employee director of the company's eighth board of directors during the second joint meeting of the third employee representative assembly scheduled for February 11, 2026 [1] Group 1 - Mr. Zhao Yong was elected as the employee director of the eighth board of directors [1] - The election was conducted in accordance with the company's shareholder meeting procedures [1] - Mr. Zhao's term will last from the date of election until the end of the eighth board's term [1]

Group 1 - The core point of the article is the election of Zhao Yong as the employee director of Shanghai Pharmaceuticals' eighth board of directors during the second joint meeting of the third employee representative assembly [1] - Zhao Yong will serve alongside directors elected by the company's shareholders, forming the complete eighth board of directors [1] - The term of Zhao Yong and the eighth board of directors will last from the date of the employee representative assembly election until the end of the eighth board's term [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) announced the election of Mr. Zhao Yong as the employee director of the company's eighth board of directors during the second joint meeting of the third employee representative assembly scheduled for February 11, 2026 [1] Group 1 - Mr. Zhao Yong was elected as the employee director of the eighth board of directors [1] - The term of Mr. Zhao Yong will last from the date of election by the employee representative assembly until the end of the eighth board's term [1] - Mr. Zhao Yong will work alongside directors elected by the company's shareholders to form the eighth board of directors [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期自主行權結果公告》、《上海醫藥集團股份有限公司關於鹽酸坦索羅辛原料藥上市申 請獲得批准的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 2 月 12 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生； ...

(股份代碼: 02607) 上海醫藥集團股份有限公司 董事名單及其角色和職能 Shanghai Pharmaceuticals Holding Co., Ltd. * 於 2026 年 2 月 11 日，上海醫藥集團股份有限公司董事會(「董事會」)成員列示如下： （於中華人民共和國註冊成立的股份有限公司） 執行董事: 楊秋華先生（董事長） 沈波先生 李永忠先生 董明先生 非執行董事: 張文學先生 霍文遜先生（召集人） 沈波先生 顧朝陽先生 萬鈞女士 審計委員會: 顧朝陽先生（召集人） 霍文遜先生 王忠先生 薪酬與考核委員會: 趙勇先生 獨立非執行董事: 顧朝陽先生 霍文遜先生 王忠先生 萬鈞女士 戰略委員會: 楊秋華先生（召集人） 張文學先生 王忠先生 提名委員會: 職工董事: 王忠先生（召集人） 楊秋華先生 顧朝陽先生 中國上海，2026 年 2 月 11 日 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) 本公司尚未與趙先生訂立董事服務合同。趙先生不就履行董事職責從公司領取董事薪酬、 津貼，根據在公司內部擔任的職務按照公司薪酬管理相關制度領取薪酬。 除上文所披露者外，就趙先生的委任而言，沒有任何根據上市規則第 13.51(2)(h)至(v)條中要 求而須予披露的資料，亦沒有任何須提請本公司股東注意的事項。 1 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 (股份代碼: 02607) 選舉職工董事 上海醫藥集團股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 於2026年2月11日召開的第三届職工代表大會第二次聯席會議上，趙勇先生（「趙先生」）獲 選舉為本公司第八屆董事會職工董事，趙先生與經本公司股東會選舉產生的董事共同 ...

上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划预留股票期权第三个行 权期自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次股权激励计划已履行的相关审批程序 1、2019 年 9 月 30 日，公司召开第七届董事会第五次会议及第七届监事会 第三次会议，审议通过了《关于 2019 年股票期权激励计划（草案）及其摘要的 议案》（以下简称"《股票期权激励计划（草案）》"）、《关于 2019 年股票期权激 励计划实施考核管理办法的议案》（以下简称"《考核管理办法》"）、《关于提请 股东大会授权董事会办理 2019 年股票期权激励计划相关事宜的议案》。公司董事 中作为激励对象的关联董事左敏先生、李永忠先生及沈波先生均已回避表决。公 司独立董事基于独立客观判断，发表独立意见同意上述事项；公司监事会亦出具 核查意见。详见公司于 2019 年 10 月 1 日在指定信息披露媒体发布的相关公告。 2、2019 年 11 月 12 日，公司收到上海市国有资产监督管理委员会出具的《关 ...